State Street SPDR Bloomberg Invstmt Gr Fltg Rt ETF vs Koninklijke Philips NV — how do they compare? State Street SPDR Bloomberg Invstmt Gr Fltg Rt ETF trades at $30.79, while Koninklijke Philips NV trades at $27.26 (market cap $26.29B). The key difference: Koninklijke Philips NV pays a 3.75% dividend while State Street SPDR Bloomberg Invstmt Gr Fltg Rt ETF pays none, and State Street SPDR Bloomberg Invstmt Gr Fltg Rt ETF is trading nearer its 52-week high, Koninklijke Philips NV nearer its low. Which is the better fit depends on your goals.
| FLRN | PHG | |
|---|---|---|
Sector | Sector/Thematic | Health |
52-Week High | $30.86 | $32.91 |
52-Week Low | $30.65 | $24.38 |
Market Cap | — | $26.29B |
Enterprise Value | — | $32.56B |
Dividend Yield | — | 3.75% |
Signals from Pluang's Aura AI — not financial advice
FLRN trades at $30.79 with no price movement in the last 24 hours. The technical picture shows a bearish trend with moving averages indicating selling pressure, though oscillators are neutral. Key financial ratios including P/E, P/S, and ROE are unavailable in the current data. Recent corporate actions include three dividend payments of $0.11 each scheduled for mid-2026, suggesting management's commitment to shareholder returns despite the current technical weakness.
The outlook for FLRN appears cautious with bearish technical signals dominating. The stock faces headwinds from the current market environment where inflation concerns are driving investors toward inflation-protected assets. Investment opportunities exist in the consistent dividend payments, but risks include the overall bearish technical setup and potential pressure from rising interest rates that could impact stock valuations broadly.
PHG trades at $27.16, up 4.22% today. The stock shows mixed signals with a bearish technical outlook but improving fundamentals, including a return to profitability in 2025 with net income of $895 million. Recent news highlights AI integration in healthcare products and new FDA clearances, supporting growth initiatives. Analyst consensus is divided with 41% buy ratings amid neutral sentiment.
The outlook is cautiously optimistic given earnings recovery and strategic partnerships, but risks include high debt levels and competitive pressures. The stock presents a value opportunity if operational improvements continue, though technical weakness suggests near-term volatility.
Trailing returns across standard periods
FLRN invests in U.S. dollar-denominated investment-grade floating rate notes with maturities under five years. It provides exposure to corporate and supranational debt whose interest payments adjust with market rates, helping to mitigate interest rate risk.
Read more on FLRN →Philips is a diversified global healthcare company operating in three segments: diagnosis and treatment, connected care, and personal health. About 50% of the company's revenue comes from the diagnosis and treatment segment, which features imaging systems, ultrasound equipment, image-guided therapy solutions and healthcare informatics. The connected care segment (27% of revenue) encompasses monitoring and analytics systems for hospitals and sleep and respiratory care devices, whereas the personal health business (remainder of revenue) includes electric toothbrushes and men's grooming and personal-care products. In 2021, Philips generated EUR 17.2 billion in sales and had 80,000 employees in over 100 countries.
Read more on PHG →